.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Cantor Fitzgerald
US Army
Healthtrust
Mallinckrodt
Teva
Chinese Patent Office
McKesson
QuintilesIMS

Generated: June 23, 2017

DrugPatentWatch Database Preview

M.V.I.-12 LYOPHILIZED Drug Profile

« Back to Dashboard

What is the patent landscape for M.v.i.-12 Lyophilized, and when can generic versions of M.v.i.-12 Lyophilized launch?

M.v.i.-12 Lyophilized is a drug marketed by Teligent Pharma Inc and is included in one NDA.

The generic ingredient in M.V.I.-12 LYOPHILIZED is ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine; riboflavin 5'-phosphate sodium; thiamine; vitamin a; vitamin e. There are six drug master file entries for this compound. Additional details are available on the ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine; riboflavin 5'-phosphate sodium; thiamine; vitamin a; vitamin e profile page.

Summary for Tradename: M.V.I.-12 LYOPHILIZED

You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM','THIAMINE','VITAMIN A','VITAMIN E') AND hsdb_drugname IS NOT NULL' at line 1
Patents:0
Applicants:1
NDAs:1
Clinical Trials: see list50